Influences of Propofol and Sevoflurane Anesthesia in Ovarian Cancer (Anesthetics) (anesthetics)
Ovarian Cancer
About this trial
This is an interventional treatment trial for Ovarian Cancer focused on measuring Primary Ovarian Cancer, Propofol, Sevoflurane, Survival
Eligibility Criteria
Inclusion Criteria: Twenty to eighty-year-old. ASA class I-III. Patients undergoing elective craniotomy for primary ovarian tumors under general anesthesia. Exclusion Criteria: Severe mental disorder Poor liver function Pregnant or lactating women Morbid obesity Have a history of allergy to any drug used in this study Non-primary ovarian cancer surgery Undergoing ovarian cancer pathological section surgery Patients with incomplete medical records Combined with other surgeries, emergency surgeries Concomitant patients with other non-ovarian cancer therapy Patients receiving palliative treatment after ovarian cancer surgery During the maintenance period of anesthesia, propofol or sevoflurane should not be used as anesthetic drugs Intraoperative combined use of multiple anesthetics (such as ketamine, dexmedetomidine, other inhalation anesthetics) Those diagnosed with benign tumors before and after surgery Patients with metastases to the ovary
Sites / Locations
- Kaohsiung Medical University Chung-Ho Memorial HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
Sevoflurane group
Propofol group
The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3).
The propofol group was both induced and maintained at an effect-site concentration (Ce) of 2.0-4.0 mcg/mL by a target-controlled infusion (TCI) system.